Among pediatric and adult patients with cystic fibrosis, the average number of chronic respiratory therapies used fell after ...

Azithromycin has been widely evaluated for its efficacy against COVID-19. The study by Timothy S C Hinks and colleagues1 adds value to the current literature, and we would like to share our comments.

The FDA approved gepotidacin (Blujepa), an oral option for the treatment of uncomplicated urogenital gonorrhea among patients ages 12 years and older, GSK announced on Thursday.

Zoliflodacin is the first of a new class of antibiotics, called spiropyrimidinetriones, that have activity against Neisseria ...

Neisseria gonorrhoeae, the microbe responsible for gonorrhoea, is developing resistance to most antibiotics, which means we ...

The bacteria behind the sexually transmitted disease gonorrhea is known for developing antibiotic resistance. Now there are two new treatment options.

Gonorrhea is a common sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. It primarily infects the ...

Zoliflodacin is noninferior to ceftriaxone plus azithromycin for the treatment of uncomplicated urogenital gonorrhea, according to a study published online Dec. 11 in The Lancet. Alison Luckey, from ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new class of antibiotic treatment for gonorrhea for the first time in more than ...

The U.S. Food and Drug Administration recently approved two new oral medicines to treat the sexually transmitted infection ...

The U.S. health regulator on Friday approved Innoviva's oral antibiotic to treat gonorrhea, a common sexually transmitted ...

The FDA has approved Blujepa for the treatment of uncomplicated urogenital gonorrhea caused by susceptible strains of Neisseria gonorrhoeae.